How would you approach patients with ALK-positive metastatic NSCLC who progress on crizotinib and subsequently alectinib?

Ideally, I would biopsy the recurrence to determine if there is a defined resistance mutation that might be targetable by brigatinib or lorlatinib. I always try to maintain TKIs as long as possible. Dose escalation might be effective, but would not be my first choice. If none of these are options, r...